• Home
  • Politics
  • Health
  • World
  • Business
  • Finance
  • Tech
  • More
    • Sports
    • Entertainment
    • Lifestyle
What's Hot

How Smart Mattresses Improve Sleep Quality For Couples

May 9, 2025

OpenAI CEO Warns: ‘Not A Huge Amount Of Time’ Until China Overpowers American AI

May 9, 2025

Short and Funny Sayings for a Happy Summer with Friends

May 9, 2025
Facebook Twitter Instagram
  • Contact
  • Privacy Policy
  • Terms & Conditions
Friday, May 9
Patriot Now NewsPatriot Now News
  • Home
  • Politics

    Security video shows brazen sexual assault of California woman by homeless man

    October 24, 2023

    Woman makes disturbing discovery after her boyfriend chases away home intruder who stabbed him

    October 24, 2023

    Poll finds Americans overwhelmingly support Israel’s war on Hamas, but younger Americans defend Hamas

    October 24, 2023

    Off-duty pilot charged with 83 counts of attempted murder after allegedly trying to shut off engines midflight on Alaska Airlines

    October 23, 2023

    Leaked audio of Shelia Jackson Lee abusively cursing staffer

    October 22, 2023
  • Health

    Disparities In Cataract Care Are A Sorry Sight

    October 16, 2023

    Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting Demand

    October 16, 2023

    Long-term steroid use should be a last resort

    October 16, 2023

    Rite Aid Files For Bankruptcy With More ‘Underperforming Stores’ To Close

    October 16, 2023

    Who’s Still Dying From Complications Related To Covid-19?

    October 16, 2023
  • World

    New York Democrat Dan Goldman Accuses ‘Conservatives in the South’ of Holding Rallies with ‘Swastikas’

    October 13, 2023

    IDF Ret. Major General Describes Rushing to Save Son, Granddaughter During Hamas Invasion

    October 13, 2023

    Black Lives Matter Group Deletes Tweet Showing Support for Hamas 

    October 13, 2023

    AOC Denounces NYC Rally Cheering Hamas Terrorism: ‘Unacceptable’

    October 13, 2023

    L.A. Prosecutors Call Out Soros-Backed Gascón for Silence on Israel

    October 13, 2023
  • Business

    OpenAI CEO Warns: ‘Not A Huge Amount Of Time’ Until China Overpowers American AI

    May 9, 2025

    Trump Announces First Post-Tariff Trade Deal

    May 8, 2025

    Electric Vehicle Sales Nosedive As GOP Takes Buzzsaw To Biden’s Mandate

    May 7, 2025

    Tyson Foods Announces It Will Bend The Knee To Trump Admin’s New Rules

    May 7, 2025

    Federal Reserve Holds Interest Rates Steady Despite Pressure From Trump

    May 7, 2025
  • Finance

    Ending China’s De Minimis Exception Brings 3 Benefits for Americans

    April 17, 2025

    The Trump Tariff Shock Should Push Indonesia to Reform Its Economy

    April 17, 2025

    Tariff Talks an Opportunity to Reinvigorate the Japan-US Alliance

    April 17, 2025

    How China’s Companies Are Responding to the US Trade War

    April 16, 2025

    The US Flip-flop Over H20 Chip Restrictions 

    April 16, 2025
  • Tech

    Cruz Confronts Zuckerberg on Pointless Warning for Child Porn Searches

    February 2, 2024

    FTX Abandons Plans to Relaunch Crypto Exchange, Commits to Full Repayment of Customers and Creditors

    February 2, 2024

    Elon Musk Proposes Tesla Reincorporates in Texas After Delaware Judge Voids Pay Package

    February 2, 2024

    Tesla’s Elon Musk Tops Disney’s Bob Iger as Most Overrated Chief Executive

    February 2, 2024

    Mark Zuckerberg’s Wealth Grew $84 Billion in 2023 as Pedophiles Target Children on Facebook, Instagram

    February 2, 2024
  • More
    • Sports
    • Entertainment
    • Lifestyle
Patriot Now NewsPatriot Now News
Home»Health»Feast Your Eyes On DARPins For Vision Loss
Health

Feast Your Eyes On DARPins For Vision Loss

July 14, 2023No Comments6 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Feast Your Eyes On DARPins For Vision Loss
Share
Facebook Twitter LinkedIn Pinterest Email

Futuristic Eye

ACCESS Health International

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision.

In 1999, I defined regenerative medicine as the collection of interventions that restore to normal function tissues and organs that have been damaged by disease, injured by trauma, or worn by time. I include a full spectrum of chemical, gene, and protein-based medicines, cell-based therapies, and biomechanical interventions that achieve that goal.

Currently, the primary treatment option for wet age-related macular degeneration involves the injection of anti-vascular endothelial growth factor. These Anti-VEGF injections can be expensive, require frequent administration, and cause adverse effects such as vision problems, eye infections, and retinal detachment. This has driven research into alternative therapies for macular degeneration, one of which is DARPins.

Macular degeneration is an age-related eye disease that affects the macula, which is the part of the retina responsible for sharp, central vision. The disease causes a progressive loss of vision that starts in the center of the visual field and can advance to total blindness.

There are two types of macular degeneration: dry and wet. Dry macular degeneration is the most common form and is characterized by the slow breakdown of cells in the macula and the accumulation of debris in the retina. Wet macular degeneration, on the other hand, is less common but more severe, as it is characterized by the growth of abnormal blood vessels underneath the retina. These blood vessels can leak and cause permanent damage to the retina, leading to rapid vision loss.

Designed Ankyrin Repeat Proteins (DARPins) are synthetic proteins that show promise as a treatment. These engineered proteins exhibit powerful therapeutic potential as they can target the factors contributing to blood vessel growth and leakage, which are characteristic traits of macular degeneration.

With their innovative design, promising preclinical and clinical data, and potential to provide a new chapter in treating retinal disorders, DARPins hold great promise for improving outcomes for patients with wet age-related macular degeneration and related conditions.

What is a DARPin?

DARPins, a class of engineered proteins, hold immense promise and have garnered significant attention due to their versatility and potential biomedical applications. These proteins are derived from ankyrin repeat motifs, which naturally occur in protein domains across various organisms.

Cartoon representation of the molecular structure of protein registered with 2qyj code.

European Bioinformatics Institute

Ankyrin repeats consist of approximately 33 amino acids. These repeats intricately fold into specific shapes, forming highly stable protein domains. This inherent stability allows ankyrin repeats to play crucial roles in diverse cellular processes, contributing to their functional diversity.

DARPins are created by repeating and rearranging these units to achieve specific binding properties and target recognition. This modular design empowers DARPins to be customized and optimized for various applications, including therapeutic agents or diagnostic tools. The exceptional specificity and affinity of DARPins make them an ideal option for binding to complex molecules, such as disease-specific biomarkers and specific protein receptors.

Benefits and Drawbacks of DARPins

DARPins offer a multitude of advantages over antibody treatments for retinal disorders. Their compact structure allows better tissue penetration, including the retina, resulting in improved therapeutic delivery. Furthermore, DARPins can be engineered with exceptional affinity and specificity for target molecules, enhancing their therapeutic efficacy while minimizing off-target effects. They also exhibit remarkable stability, resisting degradation by proteases, making them a superior choice for retinal disorder treatment.

While assessing the advantages, we must also consider the potential drawbacks. It is crucial to recognize the intricacies involved in manufacturing, which demands specialized facilities and expertise. Additionally, ongoing clinical development, regulatory approval, and managing risks associated with immunogenicity and delivery challenges require further research and advances in protein engineering to fully unlock the potential of DARPins and overcome limitations associated with their utilization.

Clinical Trials of DARPins for Retinal Diseases

Representations of a single designed ankyrin repeat domain and a multidomain DARPin® drug candidate. … [+] Molecular model of MP0250, a DARPin® drug candidate consisting of four DARPin® domains (molecular weight approximately 62 kDa). The scaffold is dark blue, and the potential target interaction residues of the individual domains are orange (human serum albumin [HSA]), cyan (hepatocyte growth factor [HGF]), and red (vascular endothelial growth factor [VEGF])

Beyond Antibodies: The DARPin® Drug Platform. BioDrugs

Among the DARPins currently in clinical trials for retinal diseases, some of the most notable candidates include abicipar pegol, RG7716, and conbercept.

Abicipar pegol is a therapeutic agent targeting vascular endothelial growth factor-A (VEGF-A) in treating neovascular age-related macular degeneration and diabetic macular edema. Clinical investigations have reported that abicipar pegol demonstrated comparability to ranibizumab regarding efficacy, with a similar safety profile. However, there are some potential limitations to the therapy, such as an increased incidence of intraocular inflammation observed in some patients compared to other anti-VEGF therapies.

RG7716 is a bispecific DARPin binding to VEGF-A and Angiopoietin-2 (Ang-2). This unique feature holds promise in effectively blocking pathological angiogenesis, thus preventing blindness. Clinical trials have reported that RG7716 shows a statistically significant improvement in best-corrected visual acuity (BCVA) over the currently accepted therapy of aflibercept injections in patients with neovascular age-related macular degeneration. However, RG7716 has been associated with mild to moderate fever in some patients, and its use is not recommended for patients with a history of significant infusion reactions.

Conbercept is an innovative fusion protein that combines a DARPin domain, specifically designed to target VEGF receptors, with a domain derived from a human immunoglobulin. Clinical trials have shown its efficacy in treating various retinal disorders, including neovascular age-related macular degeneration and macular edema associated with retinal vein occlusion. Conbercept has also exhibited higher binding affinity to VEGF than other anti-VEGF agents, resulting in superior inhibition of pathological angiogenesis. However, a potential limitation of the therapy is that it is administered through intravitreal injection, which can cause adverse effects such as intraocular inflammation or endophthalmitis.

DARPins Pave the Way for the Future

DARPins, short for Designed Ankyrin Repeat Proteins, have emerged as a highly promising class of engineered proteins. Their versatility and wide range of applications show immense potential in treating various eye-related disorders. These proteins possess significant binding properties and exceptional stability, making them well-suited for biomedical purposes. While there are challenges in manufacturing and regulatory approval, ongoing research and continuous advancements in this field steadily drive their potential even further. The exploration of DARPins holds tremendous promise for the future of healthcare and for improving patients’ lives.

To learn more about the eye, read more stories at www.williamhaseltine.com

See also  Novo pauses ads for weight loss drug Wegovy amid demand
DARPins eyes Feast loss Vision
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

Can IMEC Transition From Vision to Reality?

March 12, 2025

Mongolia Eyes India as Third Destination for Coal Exports

December 5, 2024

How To Cope With Loss During The Holiday Season

November 26, 2024

Turkmenistan Eyes Pakistan’s Gwadar Port for Trade Expansion

September 30, 2024
Add A Comment

Leave A Reply Cancel Reply

Top Posts

New York Democrat Assemblyman Patrick B. Burke o accused of sexual harassment by top aide

April 15, 2023

John Amos ‘Could Be’ Victim Of a Crime as Police Launch Investigation

June 9, 2023

Hailey Bieber Makes Embarrassing Mistake, And Fans Are Roasting Her For It

August 30, 2023

Regulators Launch Probe into Hyundai, Kia Recalls of 6.4 Million Vehicles

November 21, 2023
Don't Miss

How Smart Mattresses Improve Sleep Quality For Couples

Lifestyle May 9, 2025

Sharing a bed with your partner can be romantic… until it’s not. One of you…

OpenAI CEO Warns: ‘Not A Huge Amount Of Time’ Until China Overpowers American AI

May 9, 2025

Short and Funny Sayings for a Happy Summer with Friends

May 9, 2025

Trump Announces First Post-Tariff Trade Deal

May 8, 2025
About
About

This is your World, Tech, Health, Entertainment and Sports website. We provide the latest breaking news straight from the News industry.

We're social. Connect with us:

Facebook Twitter Instagram Pinterest
Categories
  • Business (4,111)
  • Entertainment (4,220)
  • Finance (3,202)
  • Health (1,938)
  • Lifestyle (1,628)
  • Politics (3,084)
  • Sports (4,036)
  • Tech (2,006)
  • Uncategorized (4)
  • World (3,944)
Our Picks

New Bill Would Make Assaulting Law Enforcement Officers a Deportable Offense

May 21, 2023

Best Destinations All Solo Travelers Need To Visit

December 7, 2023

Three U.S. Citizens Who Joined Cartels After Falling in Love with Drug Lords

October 2, 2023
Popular Posts

How Smart Mattresses Improve Sleep Quality For Couples

May 9, 2025

OpenAI CEO Warns: ‘Not A Huge Amount Of Time’ Until China Overpowers American AI

May 9, 2025

Short and Funny Sayings for a Happy Summer with Friends

May 9, 2025
© 2025 Patriotnownews.com - All rights reserved.
  • Contact
  • Privacy Policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.